Collegium Pharmaceutical Delivers 10.34% ROIC Versus 5.18% WACC
Collegium Pharmaceutical posts a ROIC of 10.34% and WACC of 5.18%, yielding a ROIC/WACC ratio of 1.99 that signals efficient capital deployment. Among peers, Amphastar posts a 0.99 ratio, Syndax and Enanta record negative ROICs, while Ironwood leads with a 10.01 ratio.
1. Collegium's ROIC Exceeds WACC
Collegium Pharmaceutical achieved a 10.34% return on invested capital against a WACC of 5.18%, resulting in a 1.99x ROIC/WACC ratio that underscores efficient use of capital and profitable investment decisions.
2. Peer Capital Efficiency
Amphastar's ROIC of 7.52% and WACC of 7.55% yield a 0.99x ratio, suggesting returns are barely covering capital costs. Syndax and Enanta show ROICs of -66.67% and -22.45% respectively, reflecting operational losses and poor capital utilization.
3. Ironwood Tops Peers
Ironwood Pharmaceutical leads the group with a 62.21% ROIC and 6.21% WACC, producing a 10.01x ratio that highlights its superior capital management and strong profitability compared to industry peers.